CD85a / LILRB3 antibody

Principal name

CD85a / LILRB3 antibody

Alternative names for CD85a / LILRB3 antibody

LIR-3, ILT5, LIR3, HL9, Leukocyte immunoglobulin-like receptor subfamily B member 3, Leukocyte immunoglobulin-like receptor 3, Immunoglobulin-like transcript 5, Monocyte inhibitory receptor HL9, CD85 antigen-like family member A

SwissProt ID

O75022 (Human)

Gene ID

11025 (LILRB3)

Available reactivities

Hu (Human), Ms (Mouse), Rt (Rat)

Available hosts

Rabbit, Mouse

Available applications

Dot blot (Dot), Enzyme Immunoassay (E), Western blot / Immunoblot (WB), Flow Cytometry (F), Paraffin Sections (P)

Background of CD85a / LILRB3 antibody

The innate immune system uses a wide variety of pattern recognition receptors including Toll like receptor (TLRs), scavenger receptors, and lectins to identify potential pathogens. A precise regulatory mechanism is evolved to check the balance between activation and inhibition of these receptors to avoid detrimental and inappropriate inflammatory responses. Major cell types involved in the initiation and progression of allergic inflammation responses revealed that they expressed large number of cell surface receptors including Fc(gamma)RIIB, gp49B1 and paired Ig-like receptor (PirB) that inhibit the release of pro inflammatory mediators from mast and basophils. A carefully regulated balance between activation and inhibition must be kept to avoid detrimental and inappropriate inflammatory responses. Basophils, recruited from the blood to tissues, have been implicated by their presence in diverse allergic disorders including bronchial asthma, allergic rhinitis, and cutaneous contact hypersensitivity. The murine PirB receptor and its human ortholog Ig-like transcript 2 and Ig-like transcript (LILRs) are novel inhibitory receptors for staphylococcus aureus. The PirB receptors have 3 ITIM motifs and are inhibitory type receptors. Expression of these receptors enables NIH3T3 cells to bind S. aureus. In mouse bone marrow-derived macrophages, masking of PIR-B by anti-PIR mAb or genetic deletion of PIR-B shows significantly impaired recognition of S. aureus and enhanced TLR-mediated inflammatory responses to the bacteria (1). The mammalian ortholog of PirB receptors are leukocyte Leukocyte Ig-like receptors (LILRs), they are family of Ig-like receptors encoded by several genes and are expressed on various immune cells, such as those of myeloid and lymphoid lineages (2). LILRs are divided into two types of receptors: activating-type receptors (LILRA1–A6) and inhibitory-type (LILRB1–B5).
The mouse Pir receptors are composed of two isoforms, an activating PirA and inhibitory PirB (PirB1-5) which are expressed on various hematopoietic cell lineages including B cells, mast cells, macrophages, granulocytes and DC but are not expressed on T cells and NK cells. PiRB receptors contain ITIMs in their cytoplasmic domain and inhibit activation signaling by non-receptor tyrsosine kinase signal transduction cascades upon coengagement with other activating receptors (3). Both PIR-B, as well as PIR-A and their humon ortholog LILRA and LILRB receptors can bind MHC class I molecules (3). The LILRs expression is developmentally regulated on human progenitor mast cells. Progenitor mast cells expressed cell surface inhibitory LILRB1, -B2, -B3, and -B4 and activating LILRA1, whereas, mature cord-blood derived mast cells (hMCs) has detectable levels of mRNA for multiple LILRs but none were expressed on the cell surface (4). LILRB3receptors are expressed in at least 3 variant isoforms (isoform 1, 2 and 3) with molecular weight around 76-78kDa. The chromosomal region 19q13.4 contained the human leukocyte receptor cluster (LRC) which has been shown to harbor 19 genes encoding leukocyte-expressed receptors of the immunoglobulin (Ig) superfamily. The amino acid sequences in the extracellular regions of eight of these receptors show between 63 and 84% identity to the prototypic LILR1 sequence. LIRs contain either two or four Ig domains and fall into three classes: (i) those with cytoplasmic domains containing two, three, or four immunoreceptor tyrosine-based inhibitory motif-like motifs; (ii) those with a short cytoplasmic domain and no immunoreceptor tyrosine-based inhibitory motif-like motifs; and (iii) those with no transmembrane domain represented by a single LILR molecule that is presumably secreted.

3 Item(s)

per page

Primary Antibodies

Catalog No. Host Iso. Clone Pres. React. Applications  

CD85a / LILRB3 antibody

Predicted cell location: Cytoplasm, cell membrane. Positive control: Human breast cancer tissue. Recommended dilution: 1/15-50  The image on the left is immunohistochemistry of paraffin-embedded Human breast cancer tissue using LILRB3 antibody at dilution 1/20, on the right is treated with the synthetic peptide. (Original magnification:x200) Rabbit IgG Purified Hu, Ms, Rt P
0.1 ml / €325.00
  OriGene Technologies, Inc.

CD85a / LILRB3 control peptide

CD85a / LILRB3
0.25 mg / €250.00
  Acris Antibodies GmbH

CD85a / LILRB3 (615-632) antibody

Western blot with AP10122PU-N staining a band of 78 kDa in PC-LILBR3TLR4 samples at 1:500 Rabbit Aff - Purified Hu Dot, E, WB
0.1 mg / €420.00
  Acris Antibodies GmbH

3 Item(s)

per page
  • LinkedIn